How would you approach treatment for relapsed Burkitt Lymphoma without CNS involvement?

Does your choice of regimen vary in younger vs elderly cohorts? How would your answer differ between patients who received modified Magrath vs R-EPOCH vs hyperCVAD for frontline treatment?